Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., Cytokine, Etc.); Or Binds Serum Protein, Plasma Protein (e.g., Tpa, Etc.), Or Fibrin Patents (Class 424/145.1)
-
Publication number: 20150064134Abstract: The described invention provides compositions and methods for treating asthma, a disease, condition or pathologic process whose progression is characterized by one or more of aberrant fibroblast proliferation and extracellular matrix deposition producing constriction in an airway, airway remodeling, and airway obstruction in lung tissue. The method includes administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein the therapeutic amount of the polypeptide is effective to reduce the constriction of small airway dimensions and airway obstruction, treat airway remodeling, or a combination thereof.Type: ApplicationFiled: August 29, 2014Publication date: March 5, 2015Inventors: Cynthia Lander, Colleen Brophy
-
Patent number: 8969322Abstract: The invention features extracorporeal methods for the treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The invention also features devices used for the extracorporeal treatment of subjects have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.Type: GrantFiled: May 13, 2011Date of Patent: March 3, 2015Assignee: Beth Israel Deconess Medical Center, Inc.Inventor: S. Ananth Karumanchi
-
Patent number: 8969291Abstract: The present invention is directed to methods for modulating the Th1 /Th2 cell balance toward anti-inflammatory cytokine producing cells in a subject comprising decreasing the amount, the expression, or the activity of leptin in a subject sufficient to modulate the Th1 /Th2 cell balance toward anti-inflammatory cytokine producing cells. The invention is also directed to methods of treatment of an immune-related disorder in a subject comprising decreasing the amount, the expression, or the activity of leptin in the subject sufficient to treat the immune-related disorder.Type: GrantFiled: September 7, 2010Date of Patent: March 3, 2015Assignee: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Eran Elinav
-
Patent number: 8969040Abstract: The present invention provides an anti-BMP9 (Bone morphogenetic protein-9) monoclonal antibody or an antibody fragment thereof binding to human BMP9, a hybridoma producing the antibody or the antibody fragment, a DNA encoding the antibody or the antibody fragment, a vector comprising the DNA, a transformant obtained by introduction of the vector, a method for preparing the antibody or the antibody fragment using the hybridoma or the transformant, and a therapeutic agent comprising the antibody or the antibody fragment as an active ingredient. Further, the present invention provides a pharmaceutical composition comprising the antibody or the antibody fragment as an active ingredient for the treatment of anemia such as renal anemia, cancer anemia or the like, and a method for treating anemia such as renal anemia, cancer anemia or the like using the same.Type: GrantFiled: July 2, 2013Date of Patent: March 3, 2015Assignee: Kyowa Hakko Kirin Co., LtdInventors: Kiyoshi Shimizu, Yuji Yamazaki, Tsuguo Kubota, Kaname Kimura
-
Patent number: 8968731Abstract: The present invention relates generally to the use of antagonists of G-CSF, and/or its receptor (G-CSFR) in the treatment of uveitis. The present invention contemplates, therefore, the inhibition of G-CSF or G-CSFR systemically or locally and/or the down-regulation of expression of a G-CSF or G-CSFR in the treatment of uveitis.Type: GrantFiled: October 8, 2010Date of Patent: March 3, 2015Assignee: CSL LimitedInventors: Ian Peter Wicks, Ian Keith Campbell, Ann Leckie Cornish
-
Publication number: 20150056200Abstract: In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.Type: ApplicationFiled: June 30, 2014Publication date: February 26, 2015Inventors: Jasbir Seehra, Ravindra Kumar, Jennifer Lachey, Alan Koncarevic
-
Patent number: 8961973Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.Type: GrantFiled: March 28, 2014Date of Patent: February 24, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan
-
Patent number: 8962249Abstract: The invention provides methods and compositions useful for detecting autoimmune disorders.Type: GrantFiled: December 21, 2011Date of Patent: February 24, 2015Assignee: Genentech, Inc.Inventors: Alexander Abbas, Barmak Modrek, Michael J. Townsend
-
Patent number: 8961974Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.Type: GrantFiled: March 28, 2014Date of Patent: February 24, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan
-
Publication number: 20150050238Abstract: The present invention relates to the treatment of osteoarthritis and pain using IL-1? and IL-1? binding proteins, including anti-IL-1? and anti-IL-1? antibodies and engineered multivalent and multispecific IL-1? and IL-1? binding proteins.Type: ApplicationFiled: July 29, 2014Publication date: February 19, 2015Inventor: Rajesh V. KAMATH
-
Publication number: 20150050267Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.Type: ApplicationFiled: April 14, 2014Publication date: February 19, 2015Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
-
Patent number: 8956607Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the IL-10 receptor ?(IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL- 10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.Type: GrantFiled: November 30, 2010Date of Patent: February 17, 2015Assignee: Biotest AGInventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth
-
Patent number: 8951522Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.Type: GrantFiled: April 6, 2012Date of Patent: February 10, 2015Assignees: University of Leicester, Omeros CorporationInventors: Gregory A. Demopulos, Thomas Dudler, Hans-Wilhelm Schwaeble
-
Publication number: 20150037347Abstract: A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation.Type: ApplicationFiled: October 21, 2014Publication date: February 5, 2015Inventor: Oleg llicch Epshtein
-
Patent number: 8945546Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: GrantFiled: May 23, 2012Date of Patent: February 3, 2015Assignee: Medarex, L.L.C.Inventors: Shrikant Deshpande, Haichun Huang, Mohan Srinivasan, Josephine M. Cardarelli, Changyu Wang, David Passmore, Vangipuram Rangan, Thomas E. Lane, Hans S. Keirstead, Michael T. Liu
-
Patent number: 8945553Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.Type: GrantFiled: May 21, 2013Date of Patent: February 3, 2015Assignee: Bristol-Myers Squibb CompanyInventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
-
Patent number: 8945562Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.Type: GrantFiled: November 1, 2013Date of Patent: February 3, 2015Assignee: True North Therapeutics, Inc.Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
-
Patent number: 8940305Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: July 2, 2014Date of Patent: January 27, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 8940303Abstract: Antigen binding proteins which bind to human IL-7 receptor (CD127) are provided. The antigen binding proteins are typically antibodies, and are useful in the treatment of diseases or disorders in humans, particularly autoimmune diseases such as multiple sclerosis.Type: GrantFiled: January 26, 2011Date of Patent: January 27, 2015Assignee: Glaxo Group LimitedInventors: Ian Kirby, Alex H. Taylor, Thomas Matthew Webb, Yu Xue
-
Patent number: 8940874Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.Type: GrantFiled: November 30, 2012Date of Patent: January 27, 2015Assignees: Wyeth LLC, MedImmune LimitedInventors: Geertruida M. Veldman, Monique V. Davies, Kening Song, Neil M. Wolfman, Kristie Grove Bridges, Anne Field, Caroline Russell, Viia Valge-Archer
-
Patent number: 8940883Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.Type: GrantFiled: January 31, 2013Date of Patent: January 27, 2015Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, David Gailani
-
Publication number: 20150023978Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.Type: ApplicationFiled: January 17, 2014Publication date: January 22, 2015Applicants: Baxter International Inc., Dyax Corp., Baxter Healthcare SAInventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
-
Patent number: 8936785Abstract: scFv antibodies which specifically bind selected antigens and are obtainable by a method comprising (i) selecting from a pool of soluble and stable antibody frameworks a soluble and stable framework matching best the framework of a non-human antibody against the antigen with a certain binding specificity, (ii) either providing said soluble and stable framework with CDRs that bind specifically to said antigen, or mutating the framework of said non-human antibody towards the sequence of said soluble and stable framework, to generate scFv antibodies, (iii) testing the generated antibody for solubility and stability, and testing the generated antibody for antigen binding, and (iv) selecting an scFV that is soluble, stable and binds to the antigen specifically. Also provided are pharmaceutical compositions comprising said scFv antibody, methods of treatment and diagnosis for diseases related to over expression of antigens that are specifically bound by said antibody.Type: GrantFiled: July 10, 2007Date of Patent: January 20, 2015Assignee: Esbatech, An Alcon Biomedical Research Unit, LLCInventors: Adrian Auf Der Maur, Alcide Barberis, David M. Urech, Peter Lichtlen
-
Publication number: 20150017180Abstract: A method for the treatment of a chronic inflammatory condition in a patient which comprises administration to the patient of an agent which blocks or inhibits IL-3 signalling events in the patient.Type: ApplicationFiled: May 12, 2014Publication date: January 15, 2015Applicant: CSL LimitedInventors: Gino Luigi Vairo, John Allan Hamilton, Andrew David Cook
-
Patent number: 8932591Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: May 15, 2012Date of Patent: January 13, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Publication number: 20150010544Abstract: A monoclonal secretory IgA antibody, which binds to and neutralizes human p40 (the p40 subunit of IL-12 and IL-23). The secretory antibody is useful in treating a variety of inflammatory conditions in humans.Type: ApplicationFiled: December 14, 2012Publication date: January 8, 2015Inventors: Gerardus Joseph Andreas Ariaans, Frans van Dalen, Declan Thomas Nolan
-
Publication number: 20150010573Abstract: The present invention provides stabilized pharmaceutical formulations for anti-IL-17 antibodies, comprising e.g. citrate, sodium chloride and polysorbate-80 at pH 5.7. These stabilized anti-IL-17 antibody pharmaceutical formulations can be used to treat rheumatoid arthritis, psoriasis, ankylosing spondilitis, psoriatic arthritis or multiple myeloma.Type: ApplicationFiled: March 1, 2013Publication date: January 8, 2015Applicant: Eli Lilly and CompanyInventors: Vincent John Corvari, Barbara Ann Williams, Patrick Daniel Donovan, Aaron Paul Markham
-
Publication number: 20150010477Abstract: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.Type: ApplicationFiled: September 15, 2014Publication date: January 8, 2015Inventors: Roland Martin, Henry McFarland, Bibiana Bielekova
-
Patent number: 8926978Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.Type: GrantFiled: October 24, 2012Date of Patent: January 6, 2015Assignee: AnaptysBio, Inc.Inventors: David J. King, Peter Bowers, Robert A. Horlick, Tamlyn Yee Neben
-
Patent number: 8926970Abstract: The present invention relates to the use of Rspondins, particularly Rspondin2 (Rspo2) or Rspondin3 (Rspo3) or Rspondin nucleic acids, or regulators or effectors or modulators of Rspondin, e.g. Rspo2 and/or Rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. The invention is based on the demonstration that Rspo3 and Rspo2 are angiogenesis promoters, and the identification of Rspo2 and 3 as positive regulators of vascular endothelial growth factor (VEGF). These results indicate a major role for Rspondins, particularly Rspo3 and/or Rspo2 in the signaling system during angiogenesis. The invention also relates to the use of regulators or effectors or modulators of Rspondin3, including agonists and antagonists, in the treatment of conditions where treatment involves inhibiting or promoting angiogenesis and/or vasculogenesis.Type: GrantFiled: October 8, 2013Date of Patent: January 6, 2015Assignee: Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen RechtsInventors: Christof Niehrs, Olga Kazanskaya, Bisei Okawara
-
Patent number: 8926975Abstract: The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (AS). The invention describes methods and uses for treating ankylosing spondylitis, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to reduce signs and symptoms of ankylosing spondylitis in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of ankylosing spondylitis in a subject.Type: GrantFiled: June 17, 2014Date of Patent: January 6, 2015Assignee: AbbVie Biotechnology LtdInventors: Robert L. Wong, Hartmut Kupper, John R. Medich
-
Publication number: 20150004133Abstract: The invention provides methods and compositions for reducing symptoms of steatohepatitis and/or liver fibrosis and/or hepatocellular carcinoma (HCC) in a mammalian subject in need thereof, comprising administering to the mammalian subject a therapeutic amount of a compound that reduces the level of interleukin 17 (IL-17) and/or interleukin 23 (IL-23) and/or signal transducer and activator of transcription 3 (Stat3) and/or Janus kinase 2 (Jak2). The invention's methods may comprise administering to the mammalian subject a therapeutic amount of a compound that increase the level of interleukin 22 (IL-22) and/or interleukin 25 (IL-25) and/or interleukin 27 (IL-27). The invention's methods may comprise administering to the mammalian subject a therapeutic amount of interleukin 22 (IL-22) and/or interleukin 25 (IL-25) and/or interleukin 27 (IL-27).Type: ApplicationFiled: June 6, 2014Publication date: January 1, 2015Inventors: Tatiana Kisseleva, David Brenner
-
Publication number: 20150004159Abstract: The subject matter of the present invention relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compound to interact with netrin-1 receptor and/or to inhibit the dimerization of the intracellular domain of the netrin-1 receptor expressed in tumor cells. The invention also relates to a method for predicting the presence of metastatic or aggressive cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of netrin-1. The invention further comprises kits and compounds as a medicament for the treatment of cancer such as metastatic breast cancer, related to the overexpression of netrin-1 by the tumor cells.Type: ApplicationFiled: September 15, 2014Publication date: January 1, 2015Inventors: Patrick Mehlen, Agnès Bernet, Julien Fitamant
-
Patent number: 8921526Abstract: The present invention is directed to modified antibodies, including anti-TNF? antibodies, in which C-terminal amino acids of heavy chain sequences are modified from a native sequence of proline-glycine-lysine (“PGK”) to one that includes a proline positioned between the glycine and lysine, resulting in a C-terminal sequence of proline-glycine-proline-lycine (“PGPK”). The invention further provides methods of producing and using such antibodies.Type: GrantFiled: March 12, 2014Date of Patent: December 30, 2014Assignee: AbbVie, Inc.Inventors: Chris M. Chumsae, Zehra Kaymakcalan
-
Patent number: 8920798Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: GrantFiled: November 20, 2012Date of Patent: December 30, 2014Assignee: Amgen Inc.Inventors: Huiquan Han, Hosung Min, Thomas Charles Boone
-
Patent number: 8921528Abstract: Drug compositions, fusions and conjugates are provided. The drug fusions and conjugates contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The drug compositions, fusions and conjugates have a longer in vivo half-life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.Type: GrantFiled: May 31, 2005Date of Patent: December 30, 2014Assignee: Domantis LimitedInventors: Lucy J. Holt, Ian M. Tomlinson
-
Patent number: 8916153Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.Type: GrantFiled: June 26, 2013Date of Patent: December 23, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Min M. Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
-
Patent number: 8916157Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: August 6, 2014Date of Patent: December 23, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 8916158Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: August 6, 2014Date of Patent: December 23, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 8911735Abstract: The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologs, analogs and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.Type: GrantFiled: June 15, 2012Date of Patent: December 16, 2014Assignee: Genentech, Inc.Inventors: Michael S. C. Fung, Cecily R. Y. Sun, William N. C. Sun
-
Patent number: 8911737Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.Type: GrantFiled: April 18, 2014Date of Patent: December 16, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
-
Patent number: 8911734Abstract: NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA.Type: GrantFiled: December 1, 2011Date of Patent: December 16, 2014Assignee: Alderbio Holdings LLCInventors: John A. Latham, Ethan W. Ojala, Jeffrey T. L. Smith, Benjamin H. Dutzar, Leon F. Garcia-Martinez
-
Patent number: 8911741Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: July 2, 2014Date of Patent: December 16, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 8911736Abstract: The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a Transforming Growth Factor beta (TGF?) antagonist in combination with capecitabine and ixabepilone to treat breast cancer.Type: GrantFiled: March 8, 2011Date of Patent: December 16, 2014Assignee: Genzyme CorporationInventors: Jay Harper, Scott M. Lonning, Frank James Hsu
-
Patent number: 8911733Abstract: Disclosed is the use of agents and compositions that selectively inhibit the alternative complement pathway for the inhibiting or treating physiological damage resulting from traumatic brain injury (TBI), spinal cord injury (SCI), or related conditions. Preferred reagents for use in inhibition of damage resulting from TBI or SCI include those that inhibit factor B, with anti-factor B antibodies representing a particularly preferred agent.Type: GrantFiled: May 26, 2006Date of Patent: December 16, 2014Assignees: MUSC Foundation for Research Development, The Regents of the University of Colorado, a body corporateInventors: Vernon Michael Holers, Joshua M. Thurman, Stephen Tomlinson, Philip F. Stahel
-
Publication number: 20140363432Abstract: The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.Type: ApplicationFiled: December 20, 2013Publication date: December 11, 2014Applicant: GENENTECH, INC.Inventors: Nicholas Van Bruggen, Napoleone Ferrara
-
Publication number: 20140363500Abstract: The current invention is directed to particulate or vesicular immunomodulators, like e.g. cytokines, for use in combination therapy with antibodies for treatments of a range of conditions and diseases, in particular cancer, as well as methods, compositions, and kits thereof.Type: ApplicationFiled: August 27, 2014Publication date: December 11, 2014Inventors: Charles DUMONTET, Esben A. NILSSEN
-
Publication number: 20140363422Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.Type: ApplicationFiled: January 2, 2013Publication date: December 11, 2014Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa MacAgno, Shimobi Onuoha
-
Patent number: 8906372Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.Type: GrantFiled: August 2, 2013Date of Patent: December 9, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Min Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
-
Patent number: 8906375Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: November 22, 2010Date of Patent: December 9, 2014Assignee: Wyeth LLCInventors: Lynette A. Fouser, Martin Hegen, Deborah P. Luxenberg, Margot O'Toole